CN109745359A - Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof - Google Patents
Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof Download PDFInfo
- Publication number
- CN109745359A CN109745359A CN201910175836.8A CN201910175836A CN109745359A CN 109745359 A CN109745359 A CN 109745359A CN 201910175836 A CN201910175836 A CN 201910175836A CN 109745359 A CN109745359 A CN 109745359A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood glucose
- conducive
- extract
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 122
- 239000008280 blood Substances 0.000 title claims abstract description 122
- 239000008103 glucose Substances 0.000 title claims abstract description 107
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 102
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 134
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 102
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 98
- 241000208253 Gymnema sylvestre Species 0.000 claims abstract description 61
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 52
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 51
- 229960002685 biotin Drugs 0.000 claims abstract description 49
- 235000020958 biotin Nutrition 0.000 claims abstract description 49
- 239000011616 biotin Substances 0.000 claims abstract description 49
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 31
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 30
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 26
- 241000196324 Embryophyta Species 0.000 claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 8
- 229920001661 Chitosan Polymers 0.000 claims abstract description 7
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 239000011651 chromium Substances 0.000 claims description 40
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 37
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 37
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 37
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims description 37
- 229910052804 chromium Inorganic materials 0.000 claims description 37
- 150000001875 compounds Chemical group 0.000 claims description 19
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 17
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 16
- 235000005282 vitamin D3 Nutrition 0.000 claims description 16
- 239000011647 vitamin D3 Substances 0.000 claims description 16
- 229940021056 vitamin d3 Drugs 0.000 claims description 16
- 239000011701 zinc Substances 0.000 claims description 16
- 229910052725 zinc Inorganic materials 0.000 claims description 16
- 235000016804 zinc Nutrition 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 229930183009 gymnemic acid Natural products 0.000 claims description 10
- -1 nicotinate chromium Chemical compound 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- 229930003944 flavone Natural products 0.000 claims description 8
- 235000011949 flavones Nutrition 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 6
- 150000002213 flavones Chemical class 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 150000003752 zinc compounds Chemical class 0.000 claims description 6
- 150000001845 chromium compounds Chemical class 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004246 zinc acetate Substances 0.000 claims description 3
- 235000013904 zinc acetate Nutrition 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- 239000011576 zinc lactate Substances 0.000 claims description 3
- 229940050168 zinc lactate Drugs 0.000 claims description 3
- 235000000193 zinc lactate Nutrition 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- 229940076130 chromium gluconate Drugs 0.000 claims description 2
- ANPGUZATXCGJJH-OPDGVEILSA-K chromium(3+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O ANPGUZATXCGJJH-OPDGVEILSA-K 0.000 claims description 2
- 235000020765 fenugreek extract Nutrition 0.000 claims description 2
- 229960002449 glycine Drugs 0.000 claims description 2
- 229960000314 zinc acetate Drugs 0.000 claims description 2
- GAMIYQSIKAOVTG-UHFFFAOYSA-L zinc;2-aminopentanedioate Chemical compound [Zn+2].[O-]C(=O)C(N)CCC([O-])=O GAMIYQSIKAOVTG-UHFFFAOYSA-L 0.000 claims description 2
- YZCIUWZKGIFJSQ-RGMNGODLSA-N [Cr].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Cr].C(CC)N[C@@H](CCO)C(=O)O YZCIUWZKGIFJSQ-RGMNGODLSA-N 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 23
- 239000004615 ingredient Substances 0.000 abstract description 8
- 230000007246 mechanism Effects 0.000 abstract description 8
- 230000002093 peripheral effect Effects 0.000 abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 6
- 201000009104 prediabetes syndrome Diseases 0.000 abstract description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract description 5
- 244000302512 Momordica charantia Species 0.000 abstract description 5
- 235000009811 Momordica charantia Nutrition 0.000 abstract description 5
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract description 5
- 235000018365 Momordica dioica Nutrition 0.000 abstract description 5
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 208000001280 Prediabetic State Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 240000000249 Morus alba Species 0.000 abstract description 3
- 235000008708 Morus alba Nutrition 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000001151 other effect Effects 0.000 abstract description 2
- 230000007170 pathology Effects 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 239000000419 plant extract Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 109
- 229940125396 insulin Drugs 0.000 description 55
- 102000004877 Insulin Human genes 0.000 description 54
- 108090001061 Insulin Proteins 0.000 description 54
- 230000000694 effects Effects 0.000 description 50
- 230000009471 action Effects 0.000 description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 230000000144 pharmacologic effect Effects 0.000 description 26
- 239000003814 drug Substances 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 210000000496 pancreas Anatomy 0.000 description 16
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 14
- 239000011746 zinc citrate Substances 0.000 description 14
- 235000006076 zinc citrate Nutrition 0.000 description 14
- 229940068475 zinc citrate Drugs 0.000 description 14
- 229920002527 Glycogen Polymers 0.000 description 13
- 229940096919 glycogen Drugs 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 241000240378 Gymnema latifolium Species 0.000 description 12
- 206010022489 Insulin Resistance Diseases 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 238000011017 operating method Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940046374 chromium picolinate Drugs 0.000 description 8
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 208000033808 peripheral neuropathy Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 7
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 7
- 229930016911 cinnamic acid Natural products 0.000 description 7
- 235000013985 cinnamic acid Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 7
- 201000001119 neuropathy Diseases 0.000 description 7
- 230000007823 neuropathy Effects 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 6
- 108091052347 Glucose transporter family Proteins 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- WNYFTWLTSLCQLO-UHFFFAOYSA-N [As].N1=CC=CC=C1 Chemical compound [As].N1=CC=CC=C1 WNYFTWLTSLCQLO-UHFFFAOYSA-N 0.000 description 6
- 230000023852 carbohydrate metabolic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- QOWZHEWZFLTYQP-UHFFFAOYSA-K chromium(3+);triformate Chemical compound [Cr+3].[O-]C=O.[O-]C=O.[O-]C=O QOWZHEWZFLTYQP-UHFFFAOYSA-K 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000010534 mechanism of action Effects 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 235000019605 sweet taste sensations Nutrition 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 102000003746 Insulin Receptor Human genes 0.000 description 4
- 108010001127 Insulin Receptor Proteins 0.000 description 4
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 108010028144 alpha-Glucosidases Proteins 0.000 description 4
- 229940127003 anti-diabetic drug Drugs 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000675 anti-caries Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000004110 gluconeogenesis Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000723347 Cinnamomum Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- 108010001483 Glycogen Synthase Proteins 0.000 description 2
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 description 2
- 108010065850 Tristetraprolin Proteins 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 230000006377 glucose transport Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000021147 sweet food Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- LRUBQXAKGXQBHA-UHFFFAOYSA-N (+)-Conduritol F Natural products OC1C=CC(O)C(O)C1O LRUBQXAKGXQBHA-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- WSZOLRPXRPIUPK-WCCKRBBISA-N (2s)-2-amino-4-methylsulfanylbutanoic acid;chromium Chemical compound [Cr].CSCC[C@H](N)C(O)=O WSZOLRPXRPIUPK-WCCKRBBISA-N 0.000 description 1
- VLXWTKUXVXJELF-DDRSIQBQSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4r,4ar,6ar,6bs,8s,8ar,9r,10r,12as,14ar,14br)-8,9-dihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(2s)-2-methylbutanoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane- Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)C[C@H](O)[C@@]1(CO)[C@@H](O)[C@@H](C(C[C@H]14)(C)C)OC(=O)[C@@H](C)CC)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O VLXWTKUXVXJELF-DDRSIQBQSA-N 0.000 description 1
- UOZWTEQSPIEUHT-LHNBZPRDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4r,4ar,6ar,6bs,8s,8ar,9r,10r,12as,14ar,14br)-8,9-dihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(e)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxan Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)C[C@H](O)[C@@]1(CO)[C@@H](O)[C@@H](C(C[C@H]14)(C)C)OC(=O)C(/C)=C/C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O UOZWTEQSPIEUHT-LHNBZPRDSA-N 0.000 description 1
- HCTZEWPNCZGSAE-ZIDNNZLZSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4r,4ar,6ar,6bs,8s,8ar,9r,10r,12as,14ar,14br)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-9,10-bis[[(e)-2-methylbut-2-enoyl]oxy]-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyo Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)C[C@H](O)[C@@]1(CO)[C@@H](OC(=O)C(\C)=C\C)[C@@H](C(C[C@H]14)(C)C)OC(=O)C(/C)=C/C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O HCTZEWPNCZGSAE-ZIDNNZLZSA-N 0.000 description 1
- IWLKKMZNFBKYCF-GAZXINLWSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4r,4ar,6ar,6bs,8s,8ar,9r,10r,12as,14ar,14br)-8a-(acetyloxymethyl)-8,9-dihydroxy-4-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(2s)-2-methylbutanoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-t Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)C[C@H](O)[C@@]1(COC(C)=O)[C@@H](O)[C@@H](C(C[C@H]14)(C)C)OC(=O)[C@@H](C)CC)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IWLKKMZNFBKYCF-GAZXINLWSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZAUAFFKABKNGKX-QPJJXVBHSA-N (e)-3-(2-methylphenyl)prop-2-enal Chemical compound CC1=CC=CC=C1\C=C\C=O ZAUAFFKABKNGKX-QPJJXVBHSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical class O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IWLKKMZNFBKYCF-UHFFFAOYSA-N 4'-Me ether,[6-O-acetyl-beta-D-galactopyranosyl-(1?3)-alpha-L-rhamnopyranoside],7-O-beta-D-glucopyranoside]-Noranhydroicaritin Natural products C12CC(C)(C)C(OC(=O)C(C)CC)C(O)C2(COC(C)=O)C(O)CC(C2(CCC3C4(CO)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1O IWLKKMZNFBKYCF-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 241000522254 Cassia Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000009087 Crescentia cujete Species 0.000 description 1
- 235000005983 Crescentia cujete Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- YBOHPQYSEDLDAB-UHFFFAOYSA-N Gymnemic acid II Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 YBOHPQYSEDLDAB-UHFFFAOYSA-N 0.000 description 1
- VLXWTKUXVXJELF-UHFFFAOYSA-N Gymnemic acid III Natural products C12CC(C)(C)C(OC(=O)C(C)CC)C(O)C2(CO)C(O)CC(C2(CCC3C4(CO)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1O VLXWTKUXVXJELF-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 102100029237 Hexokinase-4 Human genes 0.000 description 1
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000734572 Homo sapiens Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Proteins 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010020989 Hypogeusia Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000588278 Osmanthus heterophyllus Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102100034796 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- PHRUYNFFDRXZQY-UHFFFAOYSA-N [S].C(CCCCCCC)(=O)O Chemical compound [S].C(CCCCCCC)(=O)O PHRUYNFFDRXZQY-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000003532 cataractogenesis Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 231100000196 chemotoxic Toxicity 0.000 description 1
- 230000002604 chemotoxic effect Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- LRUBQXAKGXQBHA-GUCUJZIJSA-N conduritol A Chemical compound O[C@H]1C=C[C@@H](O)[C@H](O)[C@@H]1O LRUBQXAKGXQBHA-GUCUJZIJSA-N 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940124828 glucokinase activator Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 229930190118 gymnemasaponin Natural products 0.000 description 1
- UOZWTEQSPIEUHT-UHFFFAOYSA-N gymnemic acid-IV Natural products C12CC(C)(C)C(OC(=O)C(C)=CC)C(O)C2(CO)C(O)CC(C2(CCC3C4(CO)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1O UOZWTEQSPIEUHT-UHFFFAOYSA-N 0.000 description 1
- HCTZEWPNCZGSAE-UHFFFAOYSA-N gymnemic acid-V Natural products C12CC(C)(C)C(OC(=O)C(C)=CC)C(OC(=O)C(C)=CC)C2(CO)C(O)CC(C2(CCC3C4(CO)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1O HCTZEWPNCZGSAE-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 235000019570 hypogeusia Nutrition 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 108700038606 rat Smooth muscle Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof, including following parts by weight of component: 20-400 parts of Gymnema sylvestre extract, be conducive to blood glucose balance plant or 20-400 parts of animal extracts, 20-400 parts of antioxidant, 0.1-20 parts of biotin.The extract for being conducive to blood glucose balance is selected from: one or more of the plant extracts such as cortex cinnamomi, faenum graecum, balsam pear, mulberry leaf, pueraria lobata or chitosan oligosaccharide, chitosan.Antioxidant is one or more of alpha-lipoic acid, vitamin C and/or vitamin E.Each ingredient is mutually cooperateed with by multifactor hypoglycemic mechanism, reaches regulating and controlling blood sugar jointly, reduces fat accumulation, prevents diabete peripheral herve pathology and other complication and other effects.The present composition can be used for any oral preparation, have the crowd of metabolic system obstacle to take suitable for prediabetes and diabetic population, obesity and people with hyperlipidemia etc..
Description
Technical field
Be conducive to keep blood glucose balance and prevent diabetes and its concurrent the present invention relates to a kind of composition, especially one kind
The composition of disease.The invention further relates to the preparation methods of this composition.
Background technique
The common chronic endocrine metabolism disease of diabetes spp, it is closely bound up with living habit.With modern all living creatures
The flat raising of running water and the change of eating habit, at present diabetes prevalence sustainable growth.It is shown, is cut according to IDF latest data
Only to 2015, in global range, just there is 1 people with diabetes in every 11 adults;There are 3.18 hundred million pre-diabetics,
Diabetes prevalence is up to 8.8%, prediabetes illness rate 6.7%;If intervention is not added, to the year two thousand forty, every 10 adults
In just there is 1 people to suffer from diabetes, prediabetes crowd is up to 4.81 hundred million;In addition, having nearly one in 4.15 hundred million diabetics
Half (46.5%) crowd is not diagnosed.Hundred million dollars of the 12%(6730 of diabetes consumption global medical expense), to the year two thousand forty, diabetes
Related medical expense will break through 802,000,000,000 dollars.2017, in Chinese 1.144 hundred million diabetics (20-79 years old), there is 34,100,000
Patient age was more than 65 years old;Diabetes prevalence is 10.9%, and age-standardized illness rate is 9.7%;There are about 84993 patients to die of
Diabetes, wherein 33.8% age was less than 60 years old.The most front three country of 20-79 years old 2017 diabetic's quantity point
Not Wei China, India and the U.S., diabetic (20-79 years old) quantity is respectively 1.144 hundred million, 72,900,000 and 30,200,000.And
Global Children and teenager type 1 diabetes patient populations are about 1,100,000 within 2017, wherein the U.S., India and Brazilian patient populations
First three is occupied, China comes the 4th.International Diabetes Federation discloses the 8th edition global diabetes map, the results show that
Global diabetes adult patient (20-79 years old) had reached 4.25 hundred million by 2017 from 1.51 hundred million in 2000, increased nearly 2 times.In advance
It counts by 2045, diabetic is likely to be breached 6.29 hundred million.
It is the main purpose for the treatment of diabetes that control blood glucose, which avoids complication, long in the treatment of diabetes
It is neat using Diabetes Mellitus Knowledge education, dietary therapy, exercise therapy, drug therapy and blood sugar monitoring " five drive carriage " always since phase
Also there is the mode using operative treatment obesity II patients with type Ⅰ DM in recent years in the comprehensive treatment that head is gone forward side by side.Wherein diet
Control, movement and blood sugar monitoring need to be through entire treatments always, if simple lifestyle modification can not make glycemic control up to standard
Further drug therapy should then be started.Therefore drug therapy becomes the most important means for the treatment of diabetes, divides Western medicine, biology
Medicine, Chinese patent drug, treatment is based on Western medicine at present.It is oral according to selections such as the blood glucose level of patient, islet function and disease stages
Antidiabetic drug and (or) insulin therapy, antidiabetic drug is broadly divided into biguanides according to mechanism of action difference, alpha-glucosidase inhibits
Agent (acarbose, voglibose), Insulin secretagogues (sulfonylureas, meglitinide), insulin sensitizer (thiazolidinedione
Class), GLP-1 receptor stimulating agent, DPP-IV inhibitor, SGLT2 inhibitor and trypsin class medicine.Although Western medicine hypoglycemic
Clear mechanism, significant effect can effectively control blood sugar in diabetic patients index, but there are the drawbacks of be take for a long time can pair
Human organ causes irreversible injury, and most of patients there is drug resistance tendency after cause not stop to replace drug, to body and mind and
Economy causes centainly to bear.
In the case where taking antihypelipidemic product, taking some health care products together can also for prediabetes crowd or diabetic population
Play the effect of control blood glucose.The health care product of country's listing is in the majority based on pueraria lobata, balsam pear, mulberry-leaf extract, external product
In then based on balsam pear, green tea, faenum graecum, cortex cinnamomi, Gymnema sylvestre extract, price is relatively domestic universal higher.Prescription of the present invention
Using the combination of Chinese and western medical science and nutrition, select Gymnema sylvestre extract and cinnamomum cassia extract, be aided with antioxidant, vitamin and
The nutrients such as microelement play respective mechanism of action jointly, play in terms of being shown in control blood glucose through human feeding trial
Good effect.
In State Intellectual property right patent database, in number of patent application CN00108854, CN99103588 two pieces patent of invention
The treatment that Gymnema sylvestre extract is applied to diabetes is proposed respectively, but prescription is the application of single extract.
Summary of the invention
It is an object of the invention to provide one kind to help to maintain blood glucose balance, prevents the combination of diabetes and its complication
Object, while a kind of preparation method of the drug being also disclosed.
In order to achieve the goal above, the present invention is the following technical schemes are provided: one kind helps to maintain blood glucose balance composition
Component including following parts by weight: 20-400 parts of Gymnema sylvestre extract, be conducive to plant or the animal extracts 20- of blood glucose balance
400 parts, 20-400 parts of antioxidant, 0.1-20 parts of biotin.
The antioxidant can be the those skilled in the art such as alpha-lipoic acid, vitamin C, vitamin E expect obtain
One or more kinds of antioxidants.
The plant or animal extracts for being conducive to blood glucose balance can use: cinnamomum cassia extract, chitosan oligosaccharide, chitosan, calabash
The conceivable one kind of the those skilled in the art such as reed bar extract, Bitter Melon P.E, mulberry-leaf extract or kudzu root extract meaning
Or the two or more substances conducive to blood glucose balance.
The parts by weight of further preferred component are as follows: 30-300 parts of Gymnema sylvestre extract, 30-300 parts of cinnamomum cassia extract, antioxygen
30-300 parts of agent, 0.1-10 parts of biotin.
The still further preferably parts by weight of component are as follows: 40-200 parts of Gymnema sylvestre extract, 40-200 parts of cinnamomum cassia extract, resist
40-200 parts of oxidant, 0.1-5 parts of biotin.
It preferably, also include the minor metallic element chromium of compound form.Chromium is 0.001-0.100.
Preferably, the trace element chromium in the chromium compound may be from Organic Chromium, Cr-enriched yeast, chromium gluconate, cigarette
A combination of one or more in the raw material of other compound forms such as sour chromium, chromium methionine.
It preferably, also include the minor metallic element zinc of compound form.Zn-ef ficiency is 1-10.
Preferably, trace element zinc may be from zinc sulfate, zinc glutamate, zinc acetate, zinc lactate, Portugal in the zinc compound
A combination of one or more in other compound form raw materials such as grape saccharic acid zinc, glycine zine, Zinc-rich saccharomyces cerevisiae.
Preferably, the composition also includes Vitamin D3.Vitamin D3 is 0.001-0.015.
Preferably, gymnemic acid content is 5-50% in the Gymnema sylvestre extract.
Preferably, cortex cinnamomi flavones content is 2-20% in the cinnamomum cassia extract.
Preferably, the cinnamomum cassia extract could alternatively be chitosan oligosaccharide, chitosan or faenum graecum, balsam pear, mulberry leaf, pueraria lobata
Equal those skilled in the art anticipate conceivable one or more conducive to the substance of blood glucose balance.
Preferably, various dosage forms can be made in the composition, and preparation dosage form needs to increase auxiliary material.
Preferably, the auxiliary material can be expected for those skilled in the art such as superfine silica gel powder, talcum powder, magnesium stearates and obtain
One or more, preferred magnesium stearate.
The technical solution for completing second invention task of the application is the above-mentioned system for helping to maintain blood glucose balance composition
Preparation Method, which is characterized in that comprise the steps of:
S1, the Gymnema sylvestre extract in a kind of weight proportion for the composition for helping to maintain blood glucose balance, cortex cinnamomi are mentioned
Object, alpha-lipoic acid, biotin, chromium compound, zinc compound, Vitamin D3, auxiliary material is taken to carry out sieving processing (50-150 respectively
Mesh)
Chromium compound, biotin, the Vitamin D3 that S2, sieving of learning from else's experience are handled are sufficiently mixed uniformly;Then and in weight proportion
The mixing of 1/4 to 3/4 Gymnema sylvestre extract, obtains composition (1)
S3,3/4 to 1/4 Gymnema sylvestre extract by composition described above (1), zinc compound, remaining weight proportion, cortex cinnamomi
Extract, alpha-lipoic acid, auxiliary material are uniformly mixed to be conducive to keep the composition of blood glucose balance to this.
The beneficial effect of the present invention compared with the existing technology is:
The present composition selects the nutrients such as Chinese medical extract combination antioxidant, vitamin, minor metallic element, is sending out
The sensibility for waving on respective mechanism of action mutually collaboration enhancing pancreas islet, promotes insulin secretion, reduces pancreas islet and resists, delay sugar and
The blood glucose balance for maintaining human normal is assisted in absorption of the lipid in enteron aisle.Highest attention with Modern human populations to health, west
The hepatic and renal function damage that medicine generates in body is increasingly taken seriously.Diabetes or potential crowd, obesity and people with hyperlipidemia
Also being more prone to select some specific aims stronger the health food with auxiliary hyperglycemic improves own blood glucose and health indicator, subtracts
The taking dose of Shaoxi medicine.The specific effective effect of the present invention compared with the prior art is as follows:
1, using Chinese and western medical science combination nutritional knowledge * to prescription scientific compatibility, multiple target effect realizes a variety of function such as hypoglycemic
Effect.
The present composition selects natural plant essence, plays hypoglycemic jointly in conjunction with vitamin, microelement and alpha lipoic acid
Mechanism.
Gymnema sylvestre extract has hypoglycemic, anti-caries tooth and inhibits sweet taste using gymnemic acid ingredient as main active
The effects of reaction, inhibits absorption of the body to sugar, reduces blood glucose, and help repairs pancreas damaged cell, improves the secretion of insulin
Amount.
Cortex cinnamomi is containing many kinds of substance such as volatile oil, terpene, polysaccharide, flavonoids, phenols and saponin(es.Country's health-care series produce at present
The cinnamomum cassia extract Testing index chosen in product is based on cinnaldehydrum, polysaccharide, and wherein cinnamic acid ingredient has anti-inflammatory, antipyretic town
Bitterly, the bioactivity such as antitumor, hypoglycemic, anti-obesity, resisting oxidation free radical activity.There is enhancing to be immunized, drop blood for polysaccharide component
Sugar and other effects.This composition selects flavone component as efficiency index ingredient, passes through chalcones material incentive insulin receptor
Autophosphorylation, promote glucose absorption and Glycogen synthesis, inhibit fatty steroids.Although in cytositimulation glucose
It is direct that absorption aspects act on no medical insulin, but because Chinese medical extract has multiple target effect in vivo, is especially promoting
Glycogen closes and has similar insulin action in terms of Glycogen synthase activity, identical as insulin signaling, stimulates insulin receptor.Meat
Osmanthus flavones ingredient and insulin combination can be such that Glycogen synthesis increases after.
Alpha lipoic acid original is ratified by CFDA for treating Diabetic peripheral polyneuropathy.It is selected in the present composition
Diabetic can not only be prevented by anti-oxidation function with alpha lipoic acid, neuropathy occurs, insulin can also be promoted extensive
Multiple response, stimulation glucose synthesize hepatic glycogen, adjust function carbohydrate metabolism, are combined blood sugar decreasing effect with cortex cinnamomi flavones and gymnemic acid
It becomes apparent, has obvious synergistic function.
Biotin is also known as biotin, biotin, is water soluble vitamin, also belongs to vitamin B complex, B7.It is synthesis dimension
The necessary material of raw element C is fat and the indispensable substance of protein eubolism, can maintain human body natural's growth, development
With normal human's functional health, be conducive to the health and regeneration of cell.Diabetic's blood biotin concentration is low compared with normal person, leads to
Supplement biotin is crossed, facilitation is played to the adjusting of blood glucose.It is taken together when supplementing biotin combination minor metallic element chromium,
It can obviously reduce the blood glucose level of patients with NIDDM.
Chromium is the important composition ingredient of glucose tolerance factor, increases the activity of insulin, participate in protein synthesis and
The metabolism of nucleic acid, fat reduces body fat content.Chromium is closely related with glycometabolism, is that insulin performance blood sugar reducing function is required
Element, Cr3+ by formed in conjunction with niacin GT or with amino acid formed other organo-chromium compounds cooperate with insulin play
Its physiological function, mechanism of action are mainly that the insulin receptor adjusted on insulin and cell membrane by GTF forms disulfide bond,
Insulin is promoted to play maximal biological effect.Chromium may also act to transphosphorylase and succinic acid dehydrogenation in glucose metabolism
Enzyme increases the utilization of sugar;Promote the expression of glucose transporter (GLUT) -4mRNA, increases glucose transport.
Zn-ef ficiency: the generation of insulin needs zinc enzyme, and pancreas islet is usually present in pancreas in the form of insulin zinc, is taken the photograph
The effect of insulin for reducing blood sugar can be delayed and extend by entering Zn-ef ficiency.
Vitamin D3: generation and insulin sensitivity, Intra-islet Apoptosis and immunoprotection with diabetes etc. are equal
Relevant, internal deficiency can be such that the onset risk of 1 type and diabetes B improves.
Diabetes or patient's early period generally entail other diseases, such as hyperlipidemia, hypertension, metabolic disorder, pass through the above original
Expect it is reasonably combined, while playing hypoglycemic mechanism, can also reducing blood lipid, it is anti-oxidant, prevent neuropathy, promote body recovery just
Normal metabolic function.The present invention has further demonstrated its good result in terms of controlling blood glucose through human feeding trial.
2, insulin injection amount is reduced, mitigate patient suffering: cortex cinnamomi flavonoid active ingredient plays para-insulin sample in vivo
Mechanism of action can be reduced in right amount with periodic detection fasting blood-glucose index by doctor's advice after the diabetic of insulin injection is oral
Insulin injection amount.For patients, pain is both alleviated, financial burden is also reduced.
3, stablize diabetic's mood, be conducive to disease treatment and stabilization: because blood glucose is excessively high or unstable or complication etc. is more
Factor influences, and often mood swing is larger by diabetic, leads to poor blood glucose control.Modern medicine discovery, people are depressed
When, brain can stimulate body largely to secrete the hormone of some antagonism insulin secretions, lead to blood glucose rise.When situation is serious, even
The decomposition that can accelerate fat, increases fatty acid in blood largely, leads to ketoacidosis.The preferred stearic acid of the present composition
Magnesium is as auxiliary material, and not only because its property is stablized, while magnesium ion is to participate in a variety of physiological activities of human body and for necessary to human body
Cation has the effect of setting the mind at rest well, adjusting immunity of organism, direct inhibitory activity substance release sensitizer, in advance
Preventing bone rarefaction has with protective effect nervous system and cardiovascular and cerebrovascular, prevents migraine and hypoimmunity.In prescription
On, Vitamin D3 is used in combination, internal serotonin, dopamine and noradrenaline levels can be improved, promotes patient's feelings
Thread develops toward positive aspects, and caused depression in the case of prevention or alleviation long-term administration is more conducive to control blood glucose balance.
4, dose: it is raw material, dose that domestic hypoglycemic health-care product, which mostly uses balsam pear, pueraria lobata, mulberry leaf, American ginseng extract,
It is larger, generally 4-6 or piece.The present composition selects optional No. 0 capsule shells filling, 3 times a day, 1 tablet each time,
Opposite commercial product dose is small, easy to carry and use, and patient's degree of recognition is high, and compliance is more preferable.
The present invention is directed to onset diabetes mechanism, selects suitable active constituent and auxiliary material to carry out reasonably combined, arrives jointly
Up to Conservative restoration, stimulation beta Cell of islet, increases insulin sensitivity, improve insulin resistance, adjust the function with stabilizing blood sugar
Effect.The addition of other antioxidants can effectively remove free radical, protect peripheral nerve tissue, prevent diabete peripheral herve
The generation of lesion and complication.
1. Gymnema sylvestre extract gymnema sylvestre mainly contains the ingredients such as saponins, terpene, flavones, polypeptide and sterol substance,
Wherein oside compound is its main active.Gymnema sylvestre has 20 multinomial patents in Japan, the U.S., European application.It is printing
Popular Utilization is spent for a long time, for antitumor, solution malaria, hypoglycemic and diuresis etc..In recent years, domestic and foreign scholars study discovery gymnema sylvestre
Have the effects that hypoglycemic, anti-caries tooth and inhibits sweet taste reaction.Gymnema sylvestre can inhibit to eat the desire of sweet food, inhibit body to sugar
Absorption, reduce blood glucose, help repair pancreas damaged cell, improve the secretory volume of insulin.
(1) hypoglycemic effect: Gymnema sylvestre extract and glucose or sucrose can obviously inhibit the liter of blood glucose level when sharing
Height, and significantly reduce the secretion (tool dual regulation) of plasma insulin.In half in vitro test, gymnemic acid dose dependent
Rat small intestine sugar transport transmembrane potential difference is reduced, Na+ dependence sugar transport carrier is inhibited, reduces active of the intestinal wall to glucose
Transhipment.In the diabetes rat model caused by streptozotocin, Gymnema latifolium Wall. ex Wight extract can make the raised blood glucose value of rat and low
Serum insulin level restore to normal, and rat insulin and β cell number are multiplied, and gymnema sylvestre is prompted to pass through reparation
Or regenerating pancreas endocrine and increase insulin level, reach hypoglycemic effect and glycaemic homeostasis.Oral Gymnema latifolium Wall. ex Wight extracts
It can make the reduction of moderate alloxan diabetes rats blood glucose level after object, and this is retained potency for after drug withdrawal 2 months or more,
Serious and poisoning group does not cause blood glucose in diabetic rats to reduce, but can extend the time-to-live of rat.Gymnema latifolium Wall. ex Wight extract
Giving Type I diabetes people (insulin-dependent) can make patient decline the demand of insulin, this effect may be with regeneration
Or remaining β cell is repaired, so that it is related to enhance endogenous insulin secretion.Give 22 (non-insulins of type II diabetes people
Dependent form) after conventional hypoglycemic survival dose can be made to reduce, 5 patients can interrupt conventional antidiabetic drug, receive Gymnema latifolium Wall. ex Wight extract benefit
It fills treatment patients serum's insulin level to increase, Gymnema latifolium Wall. ex Wight extract is added in prompt can make type II diabetes people's β cytothesis
Or it repairs.Gymnema latifolium Wall. ex Wight extract has no effect on normal rat liver glycogen content, but can obviously be dropped to raising with the rat of glucose
Its low liver glycogen content, and this reduction effect of while sharing with exogenous insulin becomes apparent from.Gymnema latifolium Wall. ex Wight extract can press down
The gastrin inhibitory polypeptide of glucokinase activator processed is secreted.Gymnemic acid II, III, IV, V and of gymnemasaponin
Gymnemoside- f has inhibiting effect to rat small intestine segment glucose uptake.Separately studies have reported that Gymnema latifolium Wall. ex Wight extract
Not by stimulation exocytosis but increase membrane permeability to stimulate the release of insulin.In addition, ox more dish in gymnema sylvestre
Alcohol A 0.2mg/ml can completely inhibit absorption of the rat small intestine to glucose, show in addition to gymnemic acid, gymnema sylvestre it is hypoglycemic
Effective component further includes Conduritol A.
(2) lipid-loweringing and study of anti-atherogenic effect: Gymnema latifolium Wall. ex Wight extract reduces streptozotocin diabetes rat and increases
Serum cholesterol level, 25~100mg/kg continuous oral 2 weeks, dose dependent reduce high lipid food caused by hyperlipidemia it is big
Mouse serum triglyceride, total cholesterol, very low density lipoprotein-cholesterol and low density lipoprotein-cholesterol are horizontal, and go up
The low highdensity lipoprotein-cholesterol of hyperlipidemia rats and antiatherosclerosis index.Gymnema latifolium Wall. ex Wight extract
The drop total cholesterol of 100mg/kg, the ability of triglycerides and antiatherosclerosis and isodose lipid-loweringing comparison medicine clofibrate
It is close.Absorption of the gymnemic acid energy strong inhibition rat small intestine to oleic acid, and the effect has dose dependent and invertibity.Mouthful
Taking gymnemic acid can cause steroid excretion in rat excrement to increase.Spontaneous hypertensive rat feeds blood after gymnema sylvestre
Cholesterol concentration declines in liquid.
(3) inhibit sweet taste reaction: gymnema sylvestre may be by blocking gustatory surface sweet feel receiver to inhibit sweet taste anti-
It answers, gymnemic acid can inhibit the sweet taste of rat to feel.Chewing Gymnema latifolium Wall. ex Wight can cause hypogeusia.Gymnemic acid is that sweet taste inhibits
The main component of effect.
(4) anti-caries tooth acts on: caries preventive agent is made in Gymnema latifolium Wall. ex Wight by Japan in the form of tea, or anticarious tooth paste is made.
2. cinnamomum cassia extract is modern research shows that mainly contain volatile oil, diterpene and glucosides, flavonoids, polyphenol in cortex cinnamomi
The compounds such as class.Flavone compound has treatment cardiovascular and cerebrovascular disease, antibacterial anti-inflammatory, analgesia, antiviral and antitumor, reduction
The bioactivity such as blood glucose, reducing blood lipid and blood pressure, resisting oxidation free radical activity.Cinnamic acid is present in cortex cinnamomi in the form of transconfiguration
In volatile oil, have treatment cardiovascular and cerebrovascular disease, antibacterial, anti-inflammatory, analgesia, antiviral and antitumor, reduce blood glucose, reducing blood lipid and
The bioactivity such as blood pressure, resisting oxidation free radical activity.
(1) antidiabetic effect: the most significant feature of type 2 diabetic patient is insulin resistance, and glucose storage is caused to stay
In blood, body is made to be in hyperglycemia state.Foreign study thinks that the main mechanism of cortex cinnamomi blood sugar reducing function is 1. to reactivate
Fat cell enhances peripheral tissues and liver to the sensibility of insulin, makes peripheral tissues to Portugal to the respond of insulin
The intake of grape sugar increases;2. enhancing skeletal muscle insulin transduction signal approach, so as to improve insulin resistance;3. adjusting pancreas
The synthesis of island element signal and glycogen adjusts the boundary of hepatic glycogen;4. improve IR2 β, the tyrosine phosphorylation level of IRS2 from
And improves the adjusting of internal insulin and improve utilization of the body to glucose.It is significant that domestic related experiment thinks that cortex cinnamomi has
Hypoglycemic effect mainly plays blood sugar reducing function by the following aspects: 1. by protection, stimulation beta Cell of islet to increase blood
The content of clear insulin;2. increasing the sensibility of insulin;3. improving insulin resistance;4. removing free radical, anti-grease matter
Peroxidating;5. insulin analog effect.
Cinnamomum cassia extract can make sugar tolerance keep sensibility that is normal and enhancing body to insulin, and the phenols in CE is oligomeric
Object, which has, mitigates diabetes effect, and the CE 14d for giving various dose can be substantially reduced animal pattern blood glucose level, improves periphery
Insulin level, having reduces postprandial hyperglycemia effect.The more ketone of cinnamomum cassia extract methyl charles are to be by a kind of relative molecular mass
288 monomer, what the tetramer that the tripolymer and a kind of relative molecular mass that 2 kinds of relative molecular masses are 864 are 1152 formed
Polymer is the oligomer of A type catechin, epicatechin and procyanidine, can increase insulin-dependent in test in vitro
20 times of glycometabolism, mechanism and its can with activating glycogen synzyme and inhibition glycogen synthetase -3- kinases activity, make to expose
In the Phosphorylation of insulin receptor of the more ketone of methyl charles, excite the cascade reaction of insulin related.
IR level, enhancing in 3T3-L1 fat cell can be improved in more ketone of anthocyanidin A type polymer in cinnamomum cassia extract
Tristetraprolin (TTP) and glucose transporter (GLUT) 4 are expressed, and TTPm RNA is improved, and reduce IRm RNA, simultaneously also
Have the function of to anti-inflammatory cytokines and antiangiotensin.SUBASHBADU etc. has found that the cinnamic acid of various concentration can be with
Dose-dependent form reduces blood glucose in diabetic rats, glycosylated hemoglobin (HbAlC), total plasma cholesterol (total
Cholesterol, TC), triacylglycerol (triglycerides, TG) it is horizontal, this effect can partially restore lactic acid with it
Dehydrogenase, acid p'tase, the activity of alkaline phosphatase (ester) enzyme are related.
Polyphenol compound in cinnamon water extract can enhance the bioactivity of insulin in vitro and in vivo, and
The cortex cinnamomi polyphenol A type polymer isolated and purified is also used as the metabolism that insulin-like molecules improve internal glucose.Kim SH
Deng to cortex cinnamomi polyphenol A type polymer carry out structure of modification, obtain a kind of novel hydroxyl cinnamic acid derivative menaphthyl ester, it is right
After C57BL/Ksdb/db patients with type Ⅰ DM mouse is administered 12 weeks, the blood glucose level and peroxidatic reaction of lipid of mouse can obviously drop
It is low.Zheng H etc. has extracted a series of Cortex Cinnamomi volatile oil ingredient, the constituents energy targeted activation nuclear factor E2 correlation factor
2(Nrf2), improve metabolic disorder caused by diabetic nephropathy, protect renal function.Separately there is studies have shown that cinnamomum cassia extract that can compete
Property inhibit the activity of mammal alpha-glucosidase, reduce postprandial hyperglycemia, so that whole blood glucose tends to be steady, this and card wave
The blood sugar reducing function of sugar is similar.Ziegenfuss etc. treats 22 prediabetes and metabolic syndrome patient with cinnamomum cassia extract,
Two groups are randomly divided into, one group is given cinnamomum cassia extract, and another set gives placebo.As a result: cortex cinnamomi group fasting blood-glucose from
(116.3 ± 12.8) mg/dL drops to (106.5 ± 20.1) mg/dL, and decline 8.4%, decline is obvious, meanwhile, shrink drops
3.8%, body mass index decline 0.7%.Research prompt, cortex cinnamomi can reduce prediabetes and metabolic syndrome patient suffers from diabetes
And the risk of cardiovascular disease.Khan etc. uses placebo, gives cortex cinnamomi respectively to type 2 diabetic patient with 1,3 and 6g/d
Crude drug is oral, and after the continuous 40d that takes medicine, detection finds that each cortex cinnamomi group can be such that fasting blood glucose level is decreased obviously, and averagely reduces by 18%
~29%.It is discontinued after 20 d, repetition measurement fasting blood sugar, cortex cinnamomi 6g group fasting blood sugar before being administered still than reducing.Prompt is small dose daily
Amount (1~6g) intake cortex cinnamomi is conducive to treat and prevent diabetes B.In May, 2006 number publish " European clinical research it is miscellaneous
Will " then report, 79 take orally the cortex cinnamomi water for being equivalent to 3g crude drug in diabetes B people (men and women is fifty-fifty) continuous 4 months for each person every day
Extract, although the Hb A1C of these patients and blood lipid have no improvement, fasting blood-glucose averagely has dropped 10.3%, it can be seen that,
Chinese cassia tree water extract has some improvement to diabetes B.Crawford uses randomized controlled trial, clinical from 3 bases
Test center recruits 109 type 2 diabetic patients (HbA1c > 7.0%), is randomly divided into two groups, one group in original drug everyone
The oral cortex cinnamomi for being equivalent to 1g daily, another group is placebo, maintains 90d.The results show that cortex cinnamomi group Hb A1c has dropped
0.83% (95% CI, 0.46~1.20), placebo Hb A1c have dropped 0.37% (95% CI, 0.15~0.59), prompt
Cortex cinnamomi has therapeutic effect to diabetes B.58 type 2 diabetic patients are randomly divided into two groups by Akilen etc., and one group everyone is every
Its oral cortex cinnamomi 2g, another group uses placebo, maintains 12 weeks.The results show that cortex cinnamomi group HbA1c is down to 7.86% by 8.22%,
Systolic pressure is down to 129.2mmHg from 132.6mmHg, and diastolic pressure is down to 80.2mmHg by 85.2mmHg, and blood lipid is without substantially changeing;Peace
Console agent group experiment front and back Hb A1c, systolic pressure, diastolic pressure, blood lipid level no significant difference.As a result prompt cortex cinnamomi helps
In the HbA1c and blood pressure that reduce type 2 diabetic patient.
(2) anti-oxidant: cinnamomum cassia extract has good antioxidation, and essential oil is anti-oxidant and removing free radical activity takes
Certainly in overall oxidation resistance, remove superoxide anion (CEO), removing hydroxyl radical free radical ability, anti-linoleic acid lipid peroxidation
Ability, the ability for removing 1,1- diphenyl -2- trinitrophenyl-hydrazine (DPPH) free radical, the ethanol extract (EECC) of cortex cinnamomi are right
The inhibiting effect of lipid peroxidation is better than vitamin E in FeCl2- vitamin C rat hepatocytes homogenate, and dosage is in 0.05-
When 1.00mg/m L, the activity for removing super oxide anion and superoxides generation is most strong.
(3) anti-cardiovascular disease: modern pharmacology research shows that cortex cinnamomi can increase coronary blood flow, improves coronary artery and follows
Ring and myocardial nutrition situation, therefore it is usually used in the prevention and treatment of the cardiovascular diseases such as coronary heart disease, arrhythmia cordis, rheumatic heart disease.According to report
Road, main component cinnamic acid, cinnamic acid in Cortex Cinnamomi volatile oil etc. can protect rat model to occur together ischemia myocardial damage, this
With the two reduce it is nitric oxide production production, anti-inflammatory, oxidation resistant activity is related.Hwa JS etc. separates and extracts chemical combination from cortex cinnamomi
Object 2- methyl cinnamic aldehyde, and confirm that the compound can be reduced the endothelium of TNF-α activation using adult rat ischemia-reperfusion injury model
Cell medium vessels cell adhesion molecule 1(VCAM-1) express and induce heme oxygenase 1(HO-1) generate to improve part
Ischemia/reperfusion (I/R) damage.XueYL etc. is studies have shown that cinnamic acid can expand endothelium dependent/non-dependent rat smooth muscle
Diastole, it is related that this with it can block the channel Ca+.It is a kind of that cinnamomum cassia extract, which studies more cardiovascular protective effect,
Lignanoids compounds.The compound is a kind of novel thromboxane A2 receptor antagonist (TXA2) and the synthesis of potential thromboxane
Enzyme inhibitor is able to suppress the proliferation of the vascular smooth muscle cells of thromboxane receptor mediation, dynamic to prevention vascular diseases and treatment
Pulse atherosclerosis has latent effect.
(4) reducing blood lipid: diabetes are a kind of common endocrine metabolism diseases, are often accompanied by disorders of lipid metabolism and hyperlipemia
Disease.Long term hyperglycemia, hyperlipidemia easily induced Diabetic cardio cerebrovascular affection.In the treatment of diabetes, reducing blood lipid is almost
With it is hypoglycemic of equal importance.It is multinomial the experimental results showed that, Chinese traditional medicine cinnamon can also reduce blood lipid while hypoglycemic, prompt cortex cinnamomi
It has certain effect to the prevention and treatment tool of diabetes and its complication.The researchs such as SungHeeKim find that cinnamomum cassia extract is administered 2 weeks
Afterwards, significantly reduce db/db type mouse blood glucose level simultaneously, triacylglycerol, total cholesterol, enteral alpha-glucosidase activity are also bright
It is aobvious to reduce.Serum insulin, high-density lipoprotein (HDL) level are increased significantly (P < 0.01) compared with control group.Alam Khan etc.
60 diabetes B patients clinical medications are studied, show that cortex cinnamomi can make triacylglycerol, low-density lipoprotein (LDL), total
Cholesterol levels are decreased obviously (P < 0.05), have no significant effect to high density lipoprotein level.UbashBabuP etc. studies cinnamic acid-A tool
Play the role of reducing blood glucose, promote serum lipids reduction.Experiment is research pair with the male diabetes Wistar rat that STZ induces
As after 45d is administered in cinnamic acid, cortex cinnamomi treatment group diabetic mice blood glucose level, glycosylated hemoglobin, total cholesterol, trigalloyl are sweet
Oil level significantly reduces (P < 0.05).Plasma insulin, hepatic glycogen, HDL are horizontal significantly raised, can restore aspartate transaminase
(aspartateaminotransferase), alanine aminotransferase (alanineaminotransferase), lactic dehydrogenase
(lactatedehydrogenase), alkaline phosphatase (alkalinephosphatase) and acid p'tase
(acidphosphatase) is to normal level.
3. the utilization rate close relation of insulin in chromium, with human body, therefore it is referred to as glucose tolerance factor (letter
Claim GTF), cell can be improved to insulin sensitivity, participate in the synthesis of protein and the metabolism of nucleic acid, fat, reduce internal
Fat content.Chromium can also be such that immune system reinforces, improve body to undesirable condition with stress situation resistance.It is united according to research
Meter discovery, chromium concn in diabetic's average blood, lower than normal person 40%.Current research discovery, chromium picolinate can mention
A kind of quantity of activity AMP protein kinase (AMPK) relevant to metabolic pathway in high Skeletal Muscle Cell, to improve energy
Amount balance and insulin function.Active AMP protein kinase (AMPK) is that control includes many metabolism ways such as blood glucose Sugar intake
One important enzyme of diameter, and it is related with anti-insulin and type II diabetes.
Mending chromium, (including type 1 diabetes, diabetes B, gestational diabetes mellitus and class are solid to different types of diabetes are treated
Diabetes caused by alcohol etc.) effectively.It is better than inorganic chromium using the effect of Organic Chromium, the machine chromium of common are have chromium picolinate,
Nicotinate chromium, Cr-enriched yeast etc..The discovery chromium such as Vladeva can alleviate the insulin resistance of type 2 diabetic patient;Jovanovic
Equal propositions supplement chromium picolinate can be used as the adjuvant treatment of gestational diabetes mellitus women;The discovery chromium such as Ravina not only can treat
Type 1 diabetes, and it is also effective to diabetes caused by steroids.Chromium is played as the active constituent collaboration insulin of GTF to be made
With, to sugar, fat, protein and nucleic acid metabolism play an important role, supplement chromium have become the battalion for being suitable for diabetic
Support intervening measure.In addition, chromium helps to improve psychogenic baulimia and the caused sweet food intake of melancholy tendency is excessive.
Chromium is closely related with glycometabolism, can improve the metabolic efficiency of carbohydrate, reduces the accumulation of fat.It is solid that chromium can reduce total gallbladder
Alcohol, the concentration for improving high-density lipoprotein (HDL).The daily 200 microgram chromium of clinical studies show can reduce blood total cholesterol
Concentration.The chromium of daily 200-400 microgram facilitates body weight control, reduces ratio of the fat relative to lean tissue.Chromium is pancreas islet
Element plays element necessary to blood sugar reducing function, and Cr3+ in conjunction with niacin by forming GT or forming other organic chromaking with amino acid
It closes object collaboration insulin and plays its physiological function, mechanism of action is mainly the pancreas adjusted on insulin and cell membrane by GTF
Island element receptor forms disulfide bond, and insulin is promoted to play maximal biological effect.Chromium may also act to the phosphorus in glucose metabolism
Sour mutase and succinate dehydrogenase increase the utilization of sugar;Promote the expression of glucose transporter (GLUT) -4 mRNA, increases
Glucose transport.
4. alpha-lipoic acid (Alpha Lipoic Acid) is a kind of similar vitaminic substance, is referred to as " super antioxygen
Agent " is a kind of antioxidant of " function is at most and activity is most strong " in all antioxidants.
(1) patient is helped to reduce the dependence to insulin and hypoglycemic medicine.Alpha-lipoic acid is uniquely to have both fat-soluble and water
The omnipotent ozone agent of dissolubility can be absorbed by each tissue internal organs, and active force is also more lasting than other antioxidants.Alpha-lipoic acid energy
Enhance the absorption of diabetes B animals skeletal muscle and red blood cell to glucose, patient blood glucose can be reduced, improve cell to pancreas islet
The sensitivity of element improves the glycemic control of diabetic by balance blood sugar, and patient is made to reduce hypoglycemic medicine or delay to inject pancreas
The time of island element.
(2) diabetic's nerve fiber is protected, Peripheral neuropathy is treated in help.Foreign study proves that alpha lipoic acid can
Clinical symptoms caused by diabete peripheral herve pathology are obviously improved, are recommended for adjuvant treatment Diabetic Peripheral in Germany
Neuropathy is more than 30 years.Alpha lipoic acid can protect the nerve fiber of diabetic, reduce the incidence of neuropathy,
Inflammation caused by nerve cell is treated due to proteins deposited in help.
(3) alpha-lipoic acid is a kind of superpower antioxidant, and oxidation resistance is 5-10 times of grape pip, and grape pip
Oxidation resistance be ascorbic 20 times, 60 times of vitamin E again.The oxidative stress due to caused by hyperglycemia, free radical damage
Wound, injury of blood vessel etc. will lead to nerve cell death, cause diabetic neuropathy, and the sense such as limbs pain, numbness occurs in patient
Feel the lesions such as neuropathy and cranial nerve, autonomic nerve.And alpha-lipoic acid can regenerate antioxidant, remove free radical, weaken
Oxidative stress is gradually recovered the substances such as nerve growth factor normally, and can stimulate nerve fiber regeneration.It is reported that daily mouth
Alpha-lipoic acid is taken, less than 3 weeks, the limbs pain and pain and numbness of diabetic neuropathy patient improved, hence it is evident that discovery is through the person of controlling
Its advanced glycation end products (AGE) lowers.Experiment in vitro shows that alpha-lipoic acid has lens opacities caused by glucose
Single-minded protectiveness significantly improves crystalline intracorporal interior raw antioxidant gluthathione content, protects crystalline lens, can prevent diabetes
Cataractogenesis.In addition, alpha-lipoic acid is formed due to reducing AGE, certain effect is also functioned to diabetic angiopathy is mitigated.
Alpha-lipoic acid is each diabetes or the necessary nutriment of patient for mild hyperglycemia occurred.Middle age
After 45 years old, if there is the people of familial glycosuria disease genetic risk, even if not yet there are the clinical symptoms of diabetes, it can also drink
It food, movement, body weight control and supplements the alpha-lipoic acid of low dosage and prevents and delay the generation of diabetes.It is having occurred and that in sugar
The end of patient is urinated slightly or in the improvement of polyneuropathy, and daily taking dose is 500-600 milligrams, can divide 2-3 clothes
With being taken altogether with food as far as possible to avoid gastrointestinal discomfort phenomenon, alpha-lipoic acid needs are taken could start to play effect at least three weeks
Fruit only need to take 200-300 milligrams of alpha-lipoic acids daily for the patient of diabetes of light~moderate, general to maintain or in other
The dosage that antioxidant content merges is general only to need 20-50 milligrams or so daily.Alpha-lipoic acid is for its other than diabetes
His a variety of chronic diseases, such as the change of cardiovascular disease, liver-kidney diseases are also benefited with front.Alcohol or chemotoxic substances are made
At neuropathy there is therapeutic effect, while also contributing to the reparation of the stimulated liver cell of long-term transition.In addition, in skin
Nursing aspect lipoic acid has apparent anti-wrinkle effect, has a significant effect for prevention skin aging.
In short, alpha-lipoic acid can improve islet function and glucose metabolism, reduces AGE and form and weaken oxidative stress, have
Help the generation for preventing heart disease and cerebral apoplexy.Since supply alpha-lipoic acid can enhance insulin effect, therefore it still can be reduced patient's pancreas
The dosage of island element or antidiabetic drug.
5. biotin, i.e. biotin are conducive to the health and regeneration of cell.Diabetic can by supplement biotin
To improve the adjusting of insulin and blood glucose.Diabetes are since (long-term direct stimulation, long-term crapulence are sudden and violent for h and E factor
Food, long-term shortage movement) interaction, cause insulin absolute or hyposecretion and target tissue cell relatively is to insulin
Sensibility reduces, and causes a series of metabolic disorder syndromes such as protein, fat, water and electrolyte, is a kind of metabolic disease.
Biotin is indispensable in body generation energy process, may participate in some carbohydrate, fat and protein metabolism
The normal work of enzyme plays a significant role in the metabolic activities such as gluconeogenesis, fatty acid synthesis, the decomposition of amino acid.Supplement life
Object element can promote the decomposition of fat and carbohydrate, energy needed for making its quickening be converted to physical activity.Such as vivo biodistribution
Plain lazy weight, fat will be accumulated in vivo and cause obesity.As drug, it can be used for treating artery sclerosis, apoplexy, rouge
Class is metabolized the disease of not normal, hypertension, coronary heart disease and blood circulation disorder.
Have that researches show that diabetic's blood biotin concentration is low compared with normal person.Biotin replenishers combination minerals chromium
It takes, the blood glucose level of type 2 diabetic patient can be reduced, may be promoted by the activity of influence glycometabolism key enzyme GCK and PCK1
Sugar entering glycolysis and Glycogen synthesis and inhibit gluconeogenesis, to influence postprandial blood sugar responsion.
6. the generation of zinc compound insulin needs zinc enzyme (protaminase), and pancreas islet is usually in the form of insulin zinc
It is present in pancreas, can delays and extend the effect of insulin for reducing blood sugar.Blood sugar reducing function mechanism has: protection islet beta cell function,
Promote insulin secretion;Increase insulin sensitivity, improves insulin resistance;Inhibit alpha-glucosidase activity, delays grape
Sugar absorbs;Inhibit gluconeogenesis, promotes Glycogen synthesis;Promote utilization of the peripheral tissues to glucose;Strengthen immunity remains immune
System integrity, directly participation cellular immunity and humoral immunity overall process;Improve diabetic retina's macular degeneration etc..
7, Vitamin D3: a kind of highest active form of biological metabolism rate, the 7- generated after cholesterol dehydrogenation in vitamin D
Dehydrocholesterol can form Vitamin D3 through ultraviolet light irradiation, and generation and insulin sensitivity with diabetes, pancreas islet are thin
Born of the same parents' apoptosis and immunoprotection etc. are relevant, play important function in the occurrence and development of diabetes B, in human body
Deficiency will have the onset risk for increasing by 1 type and diabetes B.
Compared with prior art, control sugar of the invention, hypoglycemic effect are obvious, fasting blood-glucose can before taking 15.9 ±
2.06 (mmol/L) are reduced to 7.86 ± 1.06 (mmol/L);Serum cholesterol can before taking 4.70 ± 0.30
(mmol/L) 4.22 ± 0.19 (mmol/L) are reduced to.The present invention utilizes following two physiological mechanism control sugar, hypoglycemic for the first time: 1,
By prevention or the depressive emotion of reduction of patient, the balance of blood glucose is controlled.2, it is originally used for the multiple surrounding mind for the treatment of diabetes
Alpha lipoic acid through lesion can not only prevent diabetic by anti-oxidation function in the present invention and neuropathy occurs, also
Insulin can be promoted to restore response, stimulation glucose synthesizes hepatic glycogen, function carbohydrate metabolism adjusted, with cortex cinnamomi flavones and gymnema sylvestre
Acid combination blood sugar decreasing effect becomes apparent, and has obvious synergistic function.
Specific embodiment
The present invention is described in further details below by embodiment, these embodiments are only used to illustrate the present invention, and
It does not limit the scope of the invention.
Embodiment 1: be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof.
Taking parts by weight is Gymnema sylvestre extract 150, cinnamomum cassia extract 80, zinc citrate 15, magnesium stearate 4.
(1) it will organize above and carry out 80 mesh sievings processing respectively.
(2) learn from else's experience sieving processing formula ratio Gymnema sylvestre extract, cinnamomum cassia extract, zinc citrate, magnesium stearate mixing
Uniformly.
Obtain the composition for being conducive to keep blood glucose balance.
Embodiment 2
Taking parts by weight is Gymnema sylvestre extract 150, cinnamomum cassia extract 80, alpha lipoic acid 90, zinc citrate 15, magnesium stearate 4.
(1) it will organize above and carry out 80 mesh sievings processing respectively.
(2) it learns from else's experience and is sieved the formula ratio Gymnema sylvestre extract handled, cinnamomum cassia extract, alpha lipoic acid, magnesium stearate mixing
It is even.
Obtain the composition for being conducive to keep blood glucose balance.
Embodiment 3
Taking parts by weight is Gymnema sylvestre extract 150, cinnamomum cassia extract 80, alpha lipoic acid 90, zinc citrate 15, chromium picolinate
0.13, biotin 0.2, Vitamin D3 0.005, magnesium stearate 4.
(1) it will organize above and carry out 80 mesh sievings processing respectively.
(2) formula ratio chromium picolinate, the biotin that sieving of learning from else's experience is handled are sufficiently mixed uniformly;Then in recipe quantity 2/
The mixing of 3 Gymnema sylvestre extracts, obtains mixture (1).
It (3) will above (1), zinc citrate, remaining formula ratio Gymnema sylvestre extract, cinnamomum cassia extract, alpha lipoic acid, auxiliary material
It is uniformly mixed.
Obtain the composition for being conducive to keep blood glucose balance.
Embodiment 4:
Taking parts by weight is Gymnema sylvestre extract 80, chitosan 200, chromium picolinate 0.05, alpha lipoic acid 150, biotin
0.05, zinc citrate 22, superfine silica gel powder 1.
(1)-(3) operating procedure is the same as embodiment 3.
Embodiment 5
Taking parts by weight is Gymnema sylvestre extract 220, faenum graecum 30, chromium picolinate 0.2, alpha lipoic acid 50, biotin 0.3, Chinese holly
Rafter acid zinc 10, magnesium stearate 6.
(1)-(3) operating procedure is the same as embodiment 3.
Embodiment 6
Taking parts by weight is Gymnema sylvestre extract 400, cinnamomum cassia extract 400, chromium picolinate 0.2, alpha lipoic acid 50, biotin
0.3, zinc citrate 10, talcum powder 6.
(1)-(3) operating procedure is the same as embodiment 3.
Embodiment 7
Take parts by weight be Gymnema sylvestre extract 400, cinnamomum cassia extract 400, alpha-lipoic acid 400, biotin 20, nicotinate chromium 0.1,
Zinc gluconate 0.2, magnesium stearate 2.
(1)-(3) operating procedure is the same as embodiment 3.
Embodiment 8
Taking parts by weight is Gymnema sylvestre extract 300, cinnamomum cassia extract 30, alpha-lipoic acid 300, biotin 10, arsenic pyridine chromic formate
0.02, zinc citrate 0.5, magnesium stearate 3.
(1)-(3) operating procedure is the same as embodiment 3.
Embodiment 9
Taking parts by weight is Gymnema sylvestre extract 200, cinnamomum cassia extract 40, alpha-lipoic acid 200, biotin 5, arsenic pyridine chromic formate
0.02, zinc citrate 0.5, auxiliary material 3.
(1)-(3) operating procedure is the same as embodiment 3.
Embodiment 10
Taking parts by weight is Gymnema sylvestre extract 40, cinnamomum cassia extract 200, alpha-lipoic acid 40, biotin 0.1, arsenic pyridine chromic formate
0.02, zinc citrate 0.5, talcum powder 3.
(1)-(3) operating procedure is the same as embodiment 3.
Obtain the composition for being conducive to keep blood glucose balance.
Embodiment 11
Taking parts by weight is Gymnema sylvestre extract 200, cinnamomum cassia extract 200, alpha-lipoic acid 200, biotin 5, arsenic pyridine chromic formate
0.02, zinc citrate 0.5, magnesium stearate 2.
(1)-(3) operating procedure is the same as embodiment 3.
Obtain the composition for being conducive to keep blood glucose balance.
Embodiment 12
Taking parts by weight is Gymnema sylvestre extract 180, cinnamomum cassia extract 40, alpha-lipoic acid 40, biotin 4, arsenic pyridine chromic formate
0.5, zinc citrate 0.5, magnesium stearate 5.
(1)-(3) operating procedure is the same as embodiment 3.
Obtain the composition for being conducive to keep blood glucose balance.
Embodiment 13
Taking parts by weight is Gymnema sylvestre extract 300, mulberry-leaf extract 200, alpha-lipoic acid 200, biotin 2, arsenic pyridine chromic formate
0.3, zinc citrate 10, magnesium stearate 5.
(1)-(3) operating procedure is the same as embodiment 3.
Obtain the composition for being conducive to keep blood glucose balance.
Embodiment 14
Taking parts by weight is Gymnema sylvestre extract 250, kudzu root extract 200, alpha-lipoic acid 150, biotin 1.5, arsenic pyridine formic acid
Chromium 0.1, zinc citrate 18, magnesium stearate 6.
(1)-(3) operating procedure is the same as embodiment 3.
Obtain the composition for being conducive to keep blood glucose balance.
5 composition of above embodiments 1- embodiment is filling with No. 0 capsule, selects 50 diabetics to carry out test-meal and grinds
Study carefully, 3 times a day, one every time, continuously takes 2 months.As a result it see the table below.
Fasting blood-glucose, serum cholesterol variation before and after the human experiment of 5 sample of table embodiment 1- embodiment
Note: * with take it is preceding compared with, p < 0.01;# with take it is preceding compared with, p < 0.05.
P value, that is, probability reflects a possibility that a certain event occurs size.Statistics is according to obtained by significance test method
P value, be generally to have a statistical difference with P < 0.05, P < 0.01 is to have significant statistical difference, P < 0.001 be have it is extremely significant
Statistical difference.
Each 10 diabetics of above embodiments 1- embodiment 5 detect fasting blood-glucose and blood after test-meal 2 months respectively
Clear cholesterol index, five groups of patient's fasting blood-glucose indexs of discovery make moderate progress before relatively taking orally, and data have conspicuousness more afterwards
Statistical significance (P < 0.01).3 hypoglycemic effect of embodiment is substantially better than embodiment 1-2, embodiment 3-4, further demonstrates α sulphur
Octanoic acid, the importance of chromium and biotin in Regulation of blood glucose;In terms of reducing serum cholesterol, five groups of serum gallbladders are solid after taking
Alcohol index makes moderate progress before relatively taking orally, and wherein the oral front and back data of embodiment 2-5 are compared with conspicuousness statistical significance
(P < 0.01), 4 effect of embodiment are best, it was confirmed that the effect of chitosan oligosaccharide is in terms of liposuction, lipid-loweringing.
Excellent treatment effect of the composition provided by the present invention for type II diabetes.It is wherein described in embodiment 3 to control
The composition effect for treating type II diabetes and its complication is optimal, treatment type II diabetes as described in example 2 and its complication
Composition take second place;Cinnamomum cassia extract is substituted for chitosan oligosaccharide or chitosan, faenum graecum, compatibility other compositions are also specific good
Hypoglycemic effect, cortex cinnamomi effect are best.In addition, composition of the present invention also have to the complication of type II diabetes it is very good
Therapeutic effect, mitigate patient suffering, do not occur adverse reaction relevant to composition after test-meal patient is oral.
Embodiment 15, it is essentially identical with the pharmacological action of embodiment 1-14, but the composition of composition is: Gymnema sylvestre extract
20 parts, 20 parts of cinnamomum cassia extract, 20 parts of alpha-lipoic acid, 0.1 part of biotin.
Embodiment 16, it is essentially identical with the pharmacological action of embodiment 1-14, but the composition of composition is: Gymnema sylvestre extract
400 parts, 400 parts of cinnamomum cassia extract, 400 parts of alpha-lipoic acid, 20 parts of biotin.
Embodiment 17, it is essentially identical with the pharmacological action of embodiment 1-14, but the composition of composition is: Gymnema sylvestre extract
20 parts, 400 parts of cinnamomum cassia extract, 20 parts of alpha-lipoic acid, 20 parts of biotin.
Embodiment 18, it is essentially identical with the pharmacological action of embodiment 1-14, but the composition of composition is: Gymnema sylvestre extract
400 parts, 20 parts of cinnamomum cassia extract, 400 parts of alpha-lipoic acid, 0.1 part of biotin.
Embodiment 19- embodiment 22, it is essentially identical with the pharmacological action of embodiment 15-18, but the wherein described cortex cinnamomi mentions
Object is taken to be changed to chitosan oligosaccharide.Alpha-lipoic acid is changed to vitamin C.
Embodiment 23- embodiment 26, it is essentially identical with the pharmacological action of embodiment 15-18, but the wherein described cortex cinnamomi mentions
Object is taken to be changed to chitosan respectively.Alpha-lipoic acid is changed to vitamin E.
Embodiment 27- embodiment 30, it is essentially identical with the pharmacological action of embodiment 15-18, but the wherein described cortex cinnamomi mentions
Object is taken to be changed to fenugreek extract respectively.Alpha-lipoic acid is changed to the vitamin C and vitamin E of equal proportion.
Embodiment 31- embodiment 34, it is essentially identical with the pharmacological action of embodiment 15-18, but the wherein described cortex cinnamomi mentions
Object is taken to be changed to Bitter Melon P.E.
Embodiment 35- embodiment 38, it is essentially identical with the pharmacological action of embodiment 15-18, but the wherein described cortex cinnamomi mentions
Object is taken to be changed to mulberry-leaf extract.
Embodiment 39- embodiment 42, it is essentially identical with the pharmacological action of embodiment 15-18, but the wherein described cortex cinnamomi mentions
Object is taken to be changed to kudzu root extract.
Embodiment 43, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
30 parts of extract, be conducive to blood glucose balance plant or 30 parts of animal extracts, 30 parts of antioxidant, 0.1 part of biotin.
Embodiment 44, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
300 parts of extract, be conducive to blood glucose balance plant or 300 parts of animal extracts, 300 parts of antioxidant, 10 parts of biotin.
Embodiment 45, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
30 parts of extract, be conducive to blood glucose balance plant or 300 parts of animal extracts, 30 parts of antioxidant, 10 parts of biotin.
Embodiment 46, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
300 parts of extract, be conducive to blood glucose balance plant or 30 parts of animal extracts, 300 parts of antioxidant, 0.1 part of biotin.
Embodiment 47, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
40 parts of extract, be conducive to blood glucose balance plant or 40 parts of animal extracts, 40 parts of antioxidant, 0.1 part of biotin.
Embodiment 48, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
200 parts of extract, be conducive to blood glucose balance plant or 200 parts of animal extracts, 200 parts of antioxidant, 5 parts of biotin.
Embodiment 49, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
40 parts of extract, be conducive to blood glucose balance plant or 200 parts of animal extracts, 40 parts of antioxidant, 5 parts of biotin.
Embodiment 50, it is essentially identical with the pharmacological action of embodiment 1, but the parts by weight of the composition component are as follows: gymnema sylvestre
200 parts of extract, be conducive to blood glucose balance plant or 40 parts of animal extracts, 200 parts of antioxidant, 0.1 part of biotin.
Embodiment 51, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes the micro- of compound form
Metallic element chromium is measured, the parts by weight of chromium are 0.001.
Embodiment 52, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes the micro- of compound form
Metallic element chromium is measured, the parts by weight of chromium are 0.05.
Embodiment 53, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes the micro- of compound form
Metallic element zinc is measured, the parts by weight of Zn-ef ficiency are 1;The trace element zinc of the compound form is selected from: zinc sulfate, glutamic acid
Zinc, zinc acetate, zinc lactate, zinc gluconate, glycine zine, a combination of one or more in Zinc-rich saccharomyces cerevisiae.
Embodiment 53, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes the micro- of compound form
Metallic element zinc is measured, the parts by weight of Zn-ef ficiency are 10.
Embodiment 53, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes the micro gold of compound form
Belong to element zinc, the parts by weight of Zn-ef ficiency are 5.
Embodiment 54, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes Vitamin D3, gallbladder calcium
The parts by weight for changing alcohol are 0.001.
Embodiment 55, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes Vitamin D3, gallbladder calcium
The parts by weight for changing alcohol are 0.015.
Embodiment 56, it is essentially identical with the pharmacological action of embodiment 1, but the composition also includes Vitamin D3, gallbladder calcium
The parts by weight for changing alcohol are 0.008.
Compositions as described above formula and preparation are only exemplary embodiments of the invention, are not to the present invention
Make the limitation of other forms, any person skilled in the art changed possibly also with technology contents shown in above-mentioned or
It is modified as equivalent variations of equivalent embodiments.But without departing from the technical solutions of the present invention, technology according to the present invention
Essence any simple modification, equivalent variations and remodeling to the above embodiments, still fall within the protection of technical solution of the present invention
Range.
Claims (10)
1. a kind of composition for being conducive to keep blood glucose balance and prevent diabetes and its complication, which is characterized in that the combination
Object includes following parts by weight of component: 20-400 parts of Gymnema sylvestre extract, being conducive to plant or the animal extracts 20- of blood glucose balance
400 parts, 20-400 parts of antioxidant, 0.1-20 parts of biotin.
2. the composition according to claim 1 for being conducive to keep blood glucose balance and prevent diabetes and its complication,
Be characterized in that, the plant for being conducive to blood glucose balance or animal extracts are selected from: cinnamomum cassia extract, chitosan oligosaccharide, chitosan,
One or more of fenugreek extract, Bitter Melon P.E, mulberry-leaf extract or kudzu root extract are flat conducive to blood glucose
The substance of weighing apparatus.
3. the composition according to claim 1 for being conducive to keep blood glucose balance and prevent diabetes and its complication,
It is characterized in that, the antioxidant is that one or more of alpha-lipoic acid, vitamin C and/or vitamin E are anti-oxidant
Agent.
4. the composition according to claim 1 for being conducive to keep blood glucose balance and prevent diabetes and its complication,
It is characterized in that, the parts by weight of the composition component are as follows: 30-300 parts of Gymnema sylvestre extract, be conducive to the plant or dynamic of blood glucose balance
30-300 parts of object extract, 30-300 parts of antioxidant, 0.1-10 parts of biotin.
5. the composition according to claim 4 for being conducive to keep blood glucose balance and prevent diabetes and its complication,
It is characterized in that, the parts by weight of the composition component are as follows: 40-200 parts of Gymnema sylvestre extract, be conducive to the plant or dynamic of blood glucose balance
40-200 parts of object extract, 40-200 parts of antioxidant, 0.1-5 parts of biotin.
6. the composition according to claim 2 for being conducive to keep blood glucose balance and prevent diabetes and its complication,
It is characterized in that, gymnemic acid content is 5-50% in the Gymnema sylvestre extract;Cortex cinnamomi flavones content is in the cinnamomum cassia extract
2-20%。
7. special according to the composition described in claim 1 for being conducive to keep blood glucose balance and prevent diabetes and its complication
Sign is that the composition also includes the minor metallic element chromium of compound form, and the parts by weight of chromium are 0.001-
0.100;The minor metallic element chromium of the compound form is selected from: Organic Chromium, Cr-enriched yeast, chromium gluconate, nicotinate chromium, egg
The combination of one or more of propylhomoserin chromium.
8. the composition according to claim 1 for being conducive to keep blood glucose balance and prevent diabetes and its complication,
It is characterized in that, the composition also includes the minor metallic element zinc of compound form, and the parts by weight of Zn-ef ficiency are 1-10;It is described
The trace element zinc of compound form is selected from: zinc sulfate, zinc glutamate, zinc acetate, zinc lactate, zinc gluconate, glycine zine,
A combination of one or more in Zinc-rich saccharomyces cerevisiae.
9. the composition according to claim 1 for being conducive to keep blood glucose balance and prevent diabetes and its complication,
It is characterized in that, the composition also includes Vitamin D3, and the parts by weight of Vitamin D3 are 0.001-0.015.
10. the preparation of the composition as claimed in claim 9 for being conducive to keep blood glucose balance and prevention diabetes and its complication
Method, which is characterized in that the preparation method the following steps are included:
S1, the Gymnema sylvestre extract in a kind of weight proportion for the composition for helping to maintain blood glucose balance, cortex cinnamomi are mentioned
Object, alpha-lipoic acid, biotin, chromium compound, zinc compound, Vitamin D3, auxiliary material is taken to carry out 50-150 mesh sieving processing respectively;
Chromium compound, biotin, the Vitamin D3 that S2, sieving of learning from else's experience are handled are sufficiently mixed uniformly;Then and in weight proportion
The mixing of 1/4 to 3/4 Gymnema sylvestre extract, obtains composition (1);
S3,3/4 to 1/4 Gymnema sylvestre extract by composition described above (1), zinc compound, remaining weight proportion, cortex cinnamomi
Extract, alpha-lipoic acid, auxiliary material are uniformly mixed;Obtain the composition for being conducive to keep blood glucose balance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910175836.8A CN109745359A (en) | 2019-03-08 | 2019-03-08 | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910175836.8A CN109745359A (en) | 2019-03-08 | 2019-03-08 | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109745359A true CN109745359A (en) | 2019-05-14 |
Family
ID=66406915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910175836.8A Pending CN109745359A (en) | 2019-03-08 | 2019-03-08 | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109745359A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110464757A (en) * | 2019-08-16 | 2019-11-19 | 云南绿华食品有限公司 | A kind of composition and preparation method thereof reducing blood glucose using Guava Leaf |
CN110638996A (en) * | 2019-11-01 | 2020-01-03 | 博生众康(厦门)医药生物技术股份有限公司 | Blood glucose reducing compound for promoting islet regeneration and preparation method and application thereof |
CN110960620A (en) * | 2019-12-26 | 2020-04-07 | 郭晓 | Pure natural traditional Chinese medicine prescription for preventing and treating diabetes |
CN112042652A (en) * | 2020-09-08 | 2020-12-08 | 黑龙江五谷庄园生态农业科技有限公司 | Preparation of amino oligosaccharide chromium and application of amino oligosaccharide chromium to hawthorn |
CN112057581A (en) * | 2020-09-01 | 2020-12-11 | 李琳 | Medicinal and edible dual-purpose composition for rapidly reducing blood fat and blood sugar and preparation method and application thereof |
CN114190459A (en) * | 2021-12-21 | 2022-03-18 | 昆明理工大学 | Auxiliary blood sugar-reducing tea bag and preparation method thereof |
CN115554388A (en) * | 2022-11-03 | 2023-01-03 | 广州四季泰来生物技术有限公司 | Nutrition balance formula for improving female polycystic ovarian hormone level and production process |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101138577A (en) * | 2006-09-04 | 2008-03-12 | 江苏同禾药业有限公司 | Lipoic acid health food and uses thereof |
CN101437503A (en) * | 2006-02-21 | 2009-05-20 | 阿斯特鲁姆医疗有限公司 | Compositions to reduce blood glucose levels and treat diabetes |
CN101982115A (en) * | 2010-10-14 | 2011-03-02 | 张丽娜 | Composite for preventing and curing diabetes chronic sugar poisoning |
CN103463198A (en) * | 2012-06-08 | 2013-12-25 | 苏州法莫生物技术有限公司 | Traditional Chinese medicine composition for treating diabetes |
CN106474190A (en) * | 2015-10-16 | 2017-03-08 | 赫博美国际有限公司 | A kind of medicine for treating type Ⅱdiabetes mellitus and complication and preparation method thereof |
-
2019
- 2019-03-08 CN CN201910175836.8A patent/CN109745359A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437503A (en) * | 2006-02-21 | 2009-05-20 | 阿斯特鲁姆医疗有限公司 | Compositions to reduce blood glucose levels and treat diabetes |
CN101138577A (en) * | 2006-09-04 | 2008-03-12 | 江苏同禾药业有限公司 | Lipoic acid health food and uses thereof |
CN101982115A (en) * | 2010-10-14 | 2011-03-02 | 张丽娜 | Composite for preventing and curing diabetes chronic sugar poisoning |
CN103463198A (en) * | 2012-06-08 | 2013-12-25 | 苏州法莫生物技术有限公司 | Traditional Chinese medicine composition for treating diabetes |
CN106474190A (en) * | 2015-10-16 | 2017-03-08 | 赫博美国际有限公司 | A kind of medicine for treating type Ⅱdiabetes mellitus and complication and preparation method thereof |
Non-Patent Citations (3)
Title |
---|
余元勋等主编: "《中国分子糖尿病学》", 30 April 2016, 安徽科学技术出版社 * |
冯延民主编: "《壳寡糖与人类健康》", 31 March 2008, 吉林大学出版社 * |
张彩山编著: "《糖尿病治疗与保养 自我调养有方法 血糖从此不再高》", 30 June 2018, 天津科学技术出版社 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110464757A (en) * | 2019-08-16 | 2019-11-19 | 云南绿华食品有限公司 | A kind of composition and preparation method thereof reducing blood glucose using Guava Leaf |
CN110638996A (en) * | 2019-11-01 | 2020-01-03 | 博生众康(厦门)医药生物技术股份有限公司 | Blood glucose reducing compound for promoting islet regeneration and preparation method and application thereof |
CN110638996B (en) * | 2019-11-01 | 2022-07-15 | 博生众康(厦门)医药生物技术股份有限公司 | Blood glucose reducing compound for promoting islet regeneration and preparation method and application thereof |
CN110960620A (en) * | 2019-12-26 | 2020-04-07 | 郭晓 | Pure natural traditional Chinese medicine prescription for preventing and treating diabetes |
CN112057581A (en) * | 2020-09-01 | 2020-12-11 | 李琳 | Medicinal and edible dual-purpose composition for rapidly reducing blood fat and blood sugar and preparation method and application thereof |
CN112042652A (en) * | 2020-09-08 | 2020-12-08 | 黑龙江五谷庄园生态农业科技有限公司 | Preparation of amino oligosaccharide chromium and application of amino oligosaccharide chromium to hawthorn |
CN114190459A (en) * | 2021-12-21 | 2022-03-18 | 昆明理工大学 | Auxiliary blood sugar-reducing tea bag and preparation method thereof |
CN115554388A (en) * | 2022-11-03 | 2023-01-03 | 广州四季泰来生物技术有限公司 | Nutrition balance formula for improving female polycystic ovarian hormone level and production process |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109745359A (en) | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof | |
US7335651B2 (en) | Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation | |
US20020187204A1 (en) | Diet composition and method of weight management | |
WO2006127779A2 (en) | Supplement composition and method of use for enhancement of insulin sensititivy | |
CN101175416A (en) | A method and composition for nutritionally improving glucose control and insulin action | |
CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
CN110367422A (en) | A kind of rhizoma polygonati mulberry leaf compound solid beverage and preparation method thereof | |
US7879374B2 (en) | Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers | |
US11266668B2 (en) | Dietary supplement for glycemia control and diabetes prevention | |
CA3022247C (en) | Composition for treating diabetic disease | |
CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
US10757961B2 (en) | Dietary supplement for glycemia control and diabetes prevention | |
EP3860615B1 (en) | Oral composition comprising b-escin and the use thereof | |
US7416750B1 (en) | Composition to provide maintenance and nutritional support in glycemic control deficits | |
CN105106310A (en) | Health product for auxiliary reduction of blood sugar | |
CN105533596A (en) | Propolis, radix salviae miltiorrhizae and ginkgo leaf capsules and preparation method thereof | |
US20230210802A1 (en) | Composition for relieving hangover and improving liver function | |
CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
KR20070028177A (en) | Composition for controlling blood glucose level | |
KR101692546B1 (en) | A Multivitamin Composition for Alleviating Thyroid Disorders | |
KR20200056365A (en) | Composition for preventing or treating prediabetes or diabetes comrising fractionation of Gentiana scabra extracts | |
Amagase | A combination of various functional food ingredients as a weight management program: randomized, placebo-controlled, and double-blind human clinical studies | |
Dey et al. | Alternative therapies for type 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190514 |
|
RJ01 | Rejection of invention patent application after publication |